Literature DB >> 8298069

Pharmacokinetics of reversible metabolic systems.

H Cheng1, W J Jusko.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8298069     DOI： 10.1002/bdd.2510140902

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN： 0142-2782            Impact factor:   1.627


× No keyword cloud information.
  11 in total

1.  Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.

Authors:  Christelle Rodrigues; Catherine Chiron; Elisabeth Rey; Olivier Dulac; Emmanuelle Comets; Gérard Pons; Vincent Jullien
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

2.  Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.

Authors:  Peter Buchwald; Attila Juhász; Cynthia Bell; Márta Pátfalusi; John Howes; Nicholas Bodor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  Development of a complex parent-metabolite joint population pharmacokinetic model.

Authors:  Julie Bertrand; Céline M Laffont; France Mentré; Marylore Chenel; Emmanuelle Comets
Journal:  AAPS J       Date:  2011-05-27       Impact factor: 4.009

4.  Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

Authors:  Maysa Suyagh; Ahmed F Hawwa; Paul S Collier; Jeffrey S Millership; Prashant Kole; Muriel Millar; Mike D Shields; Henry L Halliday; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

Review 5.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

6.  Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

7.  The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.

Authors:  B E Davies; E A Minthorn; M J Dennis; H Rosing; J H Beijnen
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

8.  Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver.

Authors:  Y N Sun; D C DuBois; R R Almon; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-12

Review 9.  Clinical pharmacokinetics of topotecan.

Authors:  V M Herben; W W ten Bokkel Huinink; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 10.  Understanding the pharmacokinetics of reversible metabolism.

Authors:  Seungil Cho; Young-Ran Yoon
Journal:  Transl Clin Pharmacol       Date:  2019-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.